16 withdrawn. 16 Phase 2, 5 Phase 1, 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 16 | Withdrawn 16 |
| Phase 1 | 5 | Withdrawn 5 |
| Phase 3 | 2 | Withdrawn 2 |
Follow Pulmonary Disease, Chronic Obstructive: new trials by email Literature Review of Pulmonary Disease, Chronic Obstructive trials Research Report on Pulmonary Disease, Chronic Obstructive
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Oral Iloprost for the Prevention of Lung Cancer In Former Smokers Biospecimen Collection, Bronchial Brush Biopsy, Bronchoscopy - Bronchial Epithelial Dysplasia, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | National Cancer Institute (NCI) | 2024-06-01 | 2024-05-17 | |
| Tiotropium Handihaler vs. Tiotropium Respimat in COPD tiotropium bromide inhalation powder (Spiriva HandiHaler), tiotropium bromide (Spiriva Respimat), Hyperpolarized 129XeMRI - Chronic Obstructive Pulmonary Disease (COPD) | Phase 2 | Withdrawn | Duke University | 2023-05-01 | 2023-06-15 | |
| The Multicenter Topic Trial Ivacaftor - Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | University of Alabama at Birmingham | 2021-12-01 | 2022-01-27 | |
| Cycled Testosterone Administration During Pulmonary Rehabilitation in Early Stage COPD Testosterone Enanthate, Placebo - COPD | Phase 2 / Phase 3 | Withdrawn | The University of Texas Medical Branch, Galveston | 2021-12-01 | 2022-02-02 | |
| Accessing Mobility Using Wearable Sensors Exercise - COPD, Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Baylor College of Medicine | 2018-05-21 | 2025-08-27 | |
| Safety and Tolerability of Inhaled Treprostinil in Adult PH Due to COPD Inhaled Treprostinil - Pulmonary Hypertension, Chronic Obstructive Pulmonary Disease | Phase 2 | Withdrawn | United Therapeutics | 2017-04-01 | 2017-04-11 | |
| A Study of 3 Doses of Tiotropium Hydrofluoralkane (HFA) Breath Actuated Inhaler (BAI), in Patients With Chronic Obstructive Pulmonary Disease Tiotropium HFA BAI 5 mcg, Tiotropium 18 mcg Capsule, Placebo - Chronic Obstructive Pulmonary Disease, COPD | Phase 2 | Withdrawn | Teva Branded Pharmaceutical Products R&D, Inc. | 2014-08-01 | 2021-11-09 | |
| Safety and Efficacy of Adipose Derived Stem Cells for Chronic Obstructive Pulmonary Disease Lipoaspiration with Local anesthesia - Chronic Obstructive Pulmonary Disease | Phase 1 / Phase 2 | Withdrawn | Ageless Regenerative Institute | 2014-03-01 | 2017-11-24 | |
| Clinical Study of the Efficacy and Safety of the Application of Allogeneic Mesenchymal (Stromal) Cells of Bone Marrow, Cultured Under the Hypoxia in the Treatment of Patients With Severe Pulmonary Emphysema Mesenchymal stem cells, Reference therapy: 400 mL of 0.9% NaCl solution - Pulmonary Emphysema | Phase 1 / Phase 2 | Withdrawn | Federal Research Clinical Center of Federal Medical & Biological Agency, Russia | 2014-03-01 | 2018-01-09 | |
| Safety Study of Nebivolol for COPD Patients Placebo, Nebivolol - High Blood Pressure | Phase 2 / Phase 3 | Withdrawn | University of Chicago | 2012-01-01 | 2016-01-12 | |
| Cardiac Hemodynamics in Overlap Syndrome (COPD With Obstructive Sleep Apnea) Bi-level positive airway pressure (BPAP), Oxygen, CPAP - Chronic Obstructive Airway Disease | Phase 1 / Phase 2 | Withdrawn | Brigham and Women's Hospital | 2010-11-01 | 2017-01-12 | |
| Effect of an Inhaled Glucocorticoid-long-acting Beta Adrenergic Agonist on Endothelial Function in COPD Placebo, Fluticasone /salmeterol - COPD | Phase 2 | Withdrawn | University of Miami | 2010-10-01 | 2014-08-01 | |
| Efficacy and Safety of Two Doses of Formoterol Fumarate MDI (PT005) in Patients With Stable Chronic Obstructive Pulmonary Disease (COPD), Compared to Foradil® Aerolizer® as an Active Control Inhaled PT005, Inhaled Placebo, Formoterol Fumarate 12 µg (Foradil Aerolizer) - COPD | Phase 2 | Withdrawn | Pearl Therapeutics, Inc. | 2010-07-01 | 2014-07-11 | |
| Exploratory Study of Xolair in Chronic Obstructive Pulmonary Disease in Patients With Elevated IgE Levels Omalizumab (Xolair), Placebo - Pulmonary Disease, Chronic Obstructive | Phase 2 | Withdrawn | National Jewish Health | 2009-01-01 | 2017-03-29 | |
| Safety and Efficacy of 4-weeks Treatment of BIBW 2948 BS in Patients With Chronic Obstructive Bronchitis BIBW 2948 BS - Pulmonary Disease, Chronic Obstructive, Bronchitis, Chronic | Phase 2 | Withdrawn | Boehringer Ingelheim | 2008-08-01 | 2014-03-27 | |
| A Pilot Safety Study of Inhaled Dry Powder Mannitol in Acute Exacerbations of COPD mannitol - COPD, Exacerbation | Phase 1 / Phase 2 | Withdrawn | Syntara | 2006-10-01 | 2016-09-28 |
Bronchitis, Chronic (1) · Cardiovascular Diseases (1) · Emphysema (1) · Heart Failure (1) · Hypertension (1) · Hypertension, Pulmonary (1) · Hypoxia (1) · Lung Diseases (1) · Lung Neoplasms (1) · Microcephaly, Primary Autosomal Recessive, 6 (1) · Pulmonary Emphysema (1) · Sleep Apnea, Obstructive (1)
Chronic Disease (16) · Disease Attributes (16) · Lung Diseases, Obstructive (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Respiratory Tract Diseases (16) · Lung Diseases (15) · Cardiovascular Diseases (2) · Vascular Diseases (2) · Apnea (1) · Bronchial Diseases (1) · Bronchitis (1) · Dyssomnias (1) · Heart Diseases (1) · Hypertension (1)
Tiotropium Bromide (2) · Anesthesia, Local (1) · Bronchoscopy (1) · Exercise (1) · Fluticasone-Salmeterol Drug Combination (1) · Formoterol Fumarate (1) · Iloprost (1) · Lipectomy (1) · Mannitol (1) · Nebivolol (1) · Omalizumab (1) · Oxygen (1) · Specimen Handling (1) · Telerehabilitation (1) · ivacaftor (1)
Ageless Regenerative Institute (1) · Baylor College of Medicine (1) · Boehringer Ingelheim (1) · Brigham and Women's Hospital (1) · Duke University (1) · Federal Research Clinical Center of Federal Medical & Biological Agency, Russia (1) · National Cancer Institute (NCI) (1) · National Jewish Health (1) · Pearl Therapeutics, Inc. (1) · Syntara (1) · Teva Branded Pharmaceutical Products R&D, Inc. (1) · The University of Texas Medical Branch, Galveston (1) · United Therapeutics (1) · University of Alabama at Birmingham (1) · University of Chicago (1)
United States (9) · Australia (1) · France (1) · Germany (1) · Russia (1)
Adam Wanner, MD (1) · Alexander V Averyanov, MD, PhD (1) · Atul Malhotra, MD (1) · Bijan Najafi, PhD (1) · Charles Fogarty, MD (1) · David Barnes, MBBS FRACP (1) · George Bakris, MD (1) · Mark Dransfield, MD (1) · Randall J Urban, MD (1) · Russell P Bowler, MD, PhD (1) · Sharon McQuillan, MD (1) · York E Miller (1)
P30CA060553 (1), P30DK072482 (1), UG1CA242643 (1)